A frenzy around the potential of GLP-1 drugs for weight loss also hit big ASX health care names such as CSL (ASX:CSL) and ResMed. In another blow CSL’s share price slumped in February upon after announcing its well-anticipated heart attack treatment megatrial failed its primary endpoint, contributing to the overall fall of the ASX Health care index for the month of 2.70 per cent.